title: Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?
abstract: BACKGROUND
  The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer.
  
  
  METHODS
  GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. The monoclonal antibody JSB1 (DBA) at 1:20 dilution was employed for the GP-170 assay.
  
  
  RESULTS
  GP-170 expression increases with grade but was lower in multiple tumours. No difference between Ta and T1 categories was detected. GP-170 immunohistochemistry from different portions of the same tumour showed a very marked variability in 35.7% of patients. Seven patients (11.6%) were totally negative for GP-170. No statistically significant correlation was found between recurrence, progression and GP-170 basal expression. Similarly no correlation emerged between grade and stage variations at recurrence and modifications in GP-170 expression. One third of the tumours recurring after chemotherapy were negative for GP-170 in spite of an increase in recurrence rate and other risk factors.
  
  
  CONCLUSIONS
  At the present stage of our experience, we have been unable to show that GP-170 is a useful marker for monitoring chemoresistance to intravesical chemotherapy in superficial bladder cancer. Furthermore, GP-170 determination has shown several technical difficulties.
authors.affiliation: Dipartimento di Scienze Farmacologiche, Policlinico via del Vespro N. 127, 90100 Palermo, Italia. sanguedolce@unipa.it
authors.forename: Rosario
authors.initials: R
authors.lastname: Sanguedolce
authors.forename: Anna
authors.initials: A
authors.lastname: Calascibetta
authors.forename: Rossana
authors.initials: R
authors.lastname: Porcasi
authors.forename: Darwin
authors.initials: D
authors.lastname: Melloni
authors.forename: Carlo
authors.initials: C
authors.lastname: Pavone
authors.forename: Rosa Maria
authors.initials: RM
authors.lastname: Tomasino
authors.forename: Michele
authors.initials: M
authors.lastname: Pavone-Macaluso
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D000283:Administration, Intravesical; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D005260:Female; D006023:Glycoproteins / Q000096:biosynthesis* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology
chemical_list: C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D006023:Glycoproteins